Illiquid
Just hit 52 week high. One of our readers owns alot of this and Metasurface.

I see nobody else talking about it on fintwit but AT&S $ATS is quietly up a staggering 210% this year https://t.co/WrI5SjmF50 - Fenix Vanlangerode
tweet

Quiver Quantitative
JUST IN: AOC vs. $UNH CEO

"We should consider breaking up this industry" https://t.co/SVD3Qml1ep
tweet

The Few Bets That Matter
FinX Darlings & Why I Am not Buying Them.

Most investors on this platform buy the same stocks. Today' I'll go over six of them and detail why I am not.

To me, those six assets don't make the cuts and aren't worth holding today. That might change tomorrow.

1. Netflix $NFLX.

$NFLX went through a massive pivot with its ~$70B bid for $WBD. Management is guiding for a strong FY26 (12% growth, 31.5% margins), but the narrative has shifted from stable cash generation to risk taking.

The market rewards safe cash generation. Adding ~$50B in debt and spending all cash and FCF available to buy legacy IP destroys the "premium" multiple investors were willing to pay for that safe cash generation.

Is it cheap? Probably. But I’m not buying until the market digests the leverage and $NFLX proves itself capable of leveraging the IPs.

Until then, $NFLX doesn't deserve its old multiples.
tweet

Dimitry Nakhla | Babylon Capital®
ServiceNow trades 25x NTM FCF Est 💵

2026E: $5.39B (+20% YoY)

2027E: $6.52B (+20% YoY)
2028E: $7.69B (+18% YoY)

$NOW https://t.co/FAKpzSQpXX
tweet

Illiquid
A lot of everything chip related happens in Malaysia.

Many people are not aware that $INTC does much of their #AdvancedPackaging in Malaysia.
The ChipBook tracks exports of HBM from Korea to Malaysia to keep tabs on the latest Intel developments.
https://t.co/oD6GEdN2av https://t.co/M9XoUfYsdT - Chips & Wafers
tweet

The Few Bets That Matter
$TMDX dropped yesterday after news that a new competitor got FDA approval for perfusion after cold storage.

Bridge to Life’s VitaSmart was cleared for Hypothermic Oxygenated Machine Perfusion, allowing their machine to perfuse organs post cold storage, potentially allowing DCD liver transplants.

The market’s fear: a cheaper cold storage + perfusion setup could largely reduce costs and bring real competition.

But the market is ignoring a lot...

🔹OCS has consistently shown better outcomes. The device cost is negligible compared to the total cost of a failing organ (dialysis, long-term care, retransplant risk, etc)...
🔹The control of the organ's viability, automated actions and better planifications in term of surgery planning as a cold storage requires urgent intervention - hence added costs.
🔹It also ignores logistics. OCS simplifies transport, improves workflows, delivers end-to-end cost savings versus stitching together 4–5 vendors, each taking their own margin.
🔹And habits. Once a hospital owns and works with an OCS, consumables aren’t the real cost driver. Combined with better outcomes and simpler workflows, switching just doesn’t make much sense.

Yes, new cold storage solutions add competition. But they’re not a threat to $TMDX long-term potential, they are an old technology which will be used for a few more years and then be forgotten to innovation.

At best, they’re a short-term, cost-efficient alternative.
tweet

AkhenOsiris
Anthropic

Wired:

Last year, the business of AI coding agents took off. In November, Anthropic announced that Claude Code had reached $1 billion in annualized recurring revenue, less than a year after its debut.

By the end of 2025, Claude Code’s ARR had grown by at least another $100 million, according to a person familiar with the company’s financials. At the time the product accounted for roughly 12 percent of Anthropic’s total ARR, which stood around $9 billion. While still smaller than Anthropic’s enterprise business—which supplies AI systems to entire corporations—coding is one of the company’s fastest-growing segments.

Anthropic has also told investors it aims to be cash-flow positive by 2028 and that Claude Code could play an important role in its revenue growth. The company declined to comment on its finances.
tweet

AkhenOsiris
Anthropic:

While Anthropic feels dominant in AI coding, the buzz around Claude Opus 4.5 appears to be lifting several companies. Cursor, which lets users code using models from Anthropic and other AI labs, also said its coding tool reached $1 billion in ARR in November. In December, the company posted particularly strong month-over-month revenue growth, according to a person close to the company.

Anthropic

Wired:

Last year, the business of AI coding agents took off. In November, Anthropic announced that Claude Code had reached $1 billion in annualized recurring revenue, less than a year after its debut.

By the end of 2025, Claude Code’s ARR had grown by at least another $100 million, according to a person familiar with the company’s financials. At the time the product accounted for roughly 12 percent of Anthropic’s total ARR, which stood around $9 billion. While still smaller than Anthropic’s enterprise business—which supplies AI systems to entire corporations—coding is one of the company’s fastest-growing segments.

Anthropic has also told investors it aims to be cash-flow positive by 2028 and that Claude Code could play an important role in its revenue growth. The company declined to comment on its finances. - AkhenOsiris
tweet

AkhenOsiris
In the public stack, market seems confused how to price in Anthropic news...fairly straightforward how to price in OAI and Gemini...part of it is Anthropic on all clouds and no arrangement similar to OAI/MSFT...just saying

Anthropic:

While Anthropic feels dominant in AI coding, the buzz around Claude Opus 4.5 appears to be lifting several companies. Cursor, which lets users code using models from Anthropic and other AI labs, also said its coding tool reached $1 billion in ARR in November. In December, the company posted particularly strong month-over-month revenue growth, according to a person close to the company. - AkhenOsiris
tweet

God of Prompt
RT @prompt_copilot: Your AI finally has a memory.

→ Prompt enhancement
→ Autocomplete
→ Context profiles

Same you. Any AI.

Try it out 👉 https://t.co/TKMMCzVWj1 https://t.co/GMoyDegr59
tweet

The Few Bets That Matter
$BABA is pumping today on talk of a potential IPO of its AI hardware unit.

Think of it like a $GOOG IPO of its TPU business. That’s the scale we’re talking about - not the capacities.

$BABA plans to commercialize its ASICs not just as a rental product, but also to sell them directly for on-prem use by companies.

With $NVDA export curbs and ongoing tensions, this could easily become the go-to AI hardware stack in China. Even Jensen has talked about a rapidly growing ~$50B market.

From a price action standpoint, $BABA has been a gift. Same pattern printed three times. One of the easiest stocks to buy, hold and accumulate over the past two years.

Looking forward to more of this.

You don’t want to miss it, because the breakout will come. And we'll need the convictions to buy in size when it happens. Because it will.

$BABA has been frustrating for many lately.

But there is nothing wrong in consolidation. We're below the trendline, a pattern which has been repeated twice perfectly during 2025.

I’ll share a refreshed bull thesis on China and Alibaba in a few days.

You don’t want to miss it, because the breakout will come. And we'll need the convictions to buy in size when it happens. Because it will.

Patience. - The Few Bets That Matter
tweet